col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


46 Results       Page 1

 [1] 
Elsevier: Drug Discovery Today
  original article Date Title Authors   All Authors
1 [GO] 2022―Apr―06 Repurposing drugs as COVID-19 therapies: a toxicity evaluation Deborah K. Ngan, Tuan Xu, Menghang Xia, Wei Zheng, Ruili Huang
2 [GO] 2022―Feb―19 Efficacy of repurposed antiviral drugs: lessons from COVID-19 Miguel Angel Martinez
3 [GO] 2022―Feb―10 Drug repurposing against SARS-CoV-2 using computational approaches Sumit Kumar, Svitlana Kovalenko, Shakshi Bhardwaj, Aaftaab Sethi, Nikolay Yu. Gorobets, Sergey M. Desenko, Brijesh Rathi
4 [GO] 2021―Dec―23 Organoid and microfluidics-based platforms for drug screening in COVID-19 Roya Ramezankhani, Roya Solhi, Yoke Chin Chai, Massoud Vosough, Catherine Verfaillie
5 [GO] 2021―Dec―23 Applications of density functional theory in COVID-19 drug modeling Naike Ye, Zekai Yang, Yuchen Liu
6 [GO] 2021―Dec―11 Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs Rosemarie Bernabe, Cristina Torres, Grace Wangge, Edlyn Jimenez, Juntra Karbwang
7 [GO] 2021―Nov―08 The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19 Maria Sofia Basile, Eugenio Cavalli, James McCubrey, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Paolo Fagone, Ferdinando Nicoletti
8 [GO] 2021―Oct―29 Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling Gajjela Bharath Kumar, Ming-Ming Zhou
9 [GO] 2021―Oct―19 Integrating heterogeneous data to facilitate COVID-19 drug repurposing Lucía Prieto Santamaría, Marina Díaz Uzquiano, Esther Ugarte Carro, Nieves Ortiz-Roldán, Yuliana Pérez Gallardo, Alejandro Rodríguez-González
10 [GO] 2021―Jul―30 Advances in the computational landscape for repurposed drugs against COVID-19 Illya Aronskyy, Yosef Masoudi-Sobhanzadeh, Antonio Cappuccio, Elena Zaslavsky
11 [GO] 2021―Jul―29 Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management Vivek P. Chavda, Lalitkumar K. Vora, Anjali K. Pandya, Vandana B. Patravale
12 [GO] 2021―Jul―28 Harnessing the power of microphysiological systems for COVID-19 research Nicole Kleinstreuer, Anthony Holmes
13 [GO] 2021―Jun―18 Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms Guillermo Aquino-Jarquin
14 [GO] 2021―May―25 High-throughput screening assays for SARS-CoV-2 drug development: current status and future directions Tuan Xu, Wei Zheng, Ruili Huang
15 [GO] 2021―Apr―29 Revamping the Ever-changing Landscape of Drug Development Processes in the Midst of COVID-19 Pandemic Charles Oo, Barbara Ameer
16 [GO] 2021―Apr―21 Web resources facilitate drug discovery in treatment of COVID-19 Long-Can Mei, Yin Jin, Zheng Wang, Ge-Fei Hao, Guang-Fu Yang
17 [GO] 2021―Apr―21 The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects Tingting Qiu, Yitong Wang, Shuyao Liang, Ru Han, Mondher Toumi
18 [GO] 2021―Apr―16 The fight against COVID-19: striking a balance in the renin-angiotensin system Alexis Q. Dean, William P. Bozza, Julianne D. Twomey, Shen Luo, Ancy Nalli, Baolin Zhang
19 [GO] 2021―Mar―26 Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2 Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, Ryoko Wada, Eliezer Masliah, Makoto Hashimoto
20 [GO] 2021―Feb―21 Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? Mary EW Collier, Shaowei Zhang, Nigel S Scrutton, Flaviano Giorgini
21 [GO] 2021―Feb―18 Developing new drugs that activate the protective arm of the renin angiotensin system as a potential treatment for respiratory failure in COVID-19 patients Mathilde Latil, Serge Camelo, Stanislas Veillet, René Lafont, Pierre J. Dilda
22 [GO] 2021―Jan―23 SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights Prakash VasanthiDharmalingam, Vengadeshprabhu Karuppagounder, Kenichi Watanabe, Harry Karmouty-Quintana, Suresh S. Palaniyandi, Ashrith Guha, Rajarajan A. Thandavarayan
23 [GO] 2021―Jan―22 Drugs acting on the renin-angiotensin system and SARS-CoV-2 A. Vitiello, C. Pelliccia, Francesco Ferrara
24 [GO] 2021―Jan―14 Modelling the World - can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic? Adrian Wildfire
25 [GO] 2020―Dec―09 Potential SARS-CoV-2 main protease inhibitors Riddhidev Banerjee, Lalith Perera, L.M. Viranga Tillekeratne
26 [GO] 2020―Nov―27 Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic John G. Rizk, Donald N. Forthal, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, et al. (+2)
27 [GO] 2020―Oct―27 Union is strength: antiviral and anti-inflammatory drugs for COVID-19 J. Jesús Naveja, Abraham Madariaga-Mazón, Francisco Flores-Murrieta, Julio Granados-Montiel, Marco Maradiaga-Ceceña, Víctor Duarte Alaniz, et al. (+4)
28 [GO] 2020―Oct―06 Virus-, host-, immune-based targets for COVID-19 therapy Wei Liu, Hai-Liang Zhu, Yongtao Duan
29 [GO] 2020―Sep―16 Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms Nitesh Sanghai, Geoffrey K. Tranmer
30 [GO] 2020―Sep―01 Could PROTACs Protect Us From COVID-19? Wilnelly Martinez-Ortiz, Ming-Ming Zhou
31 [GO] 2020―Aug―12 Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad Mroueh, et al. (+2)
32 [GO] 2020―Aug―07 Global clinical trial mobilization for COVID-19: higher, faster, stronger Reed F. Beall, Aidan Hollis
33 [GO] 2020―Jul―04 Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges Raymond Chang, Wei-Zen Sun
34 [GO] 2020―Jun―25 Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders Bruno O. Villoutreix, Philippe H. Beaune, Ryad Tamouza, Rajogapal Krishnamoorthy, Marion Leboyer
35 [GO] 2020―Jun―24 Emerging vaccine delivery systems for COVID-19 Nigel Theobald
36 [GO] 2020―Jun―24 Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19 Rajendran J.C. Bose, Jason R. McCarthy
37 [GO] 2020―Jun―20 Current and future therapeutical approaches for COVID-19 Yongtao Duan, Yongfang Yao, Senthil Arun Kumar, Hai-Liang Zhu, Junbiao Chang
38 [GO] 2020―Jun―20 Discovering small-molecule therapeutics against SARS-CoV-2 Vaibhav Tiwari, Jacob C. Beer, Nehru Viji Sankaranarayanan, Michelle Swanson-Mungerson, Umesh R. Desai
39 [GO] 2020―Jun―18 COVID-19 and pneumonia: a role for the uPA/uPAR system Daniele D’Alonzo, Maria De Fenza, Vincenzo Pavone
40 [GO] 2020―May―13 Shotgun drug repurposing biotechnology to tackle epidemics and pandemics William Mangione, Zackary Falls, Thomas Melendy, Gaurav Chopra, Ram Samudrala
41 [GO] 2020―May―06 Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment Lorraine O’Driscoll
42 [GO] 2020―May―01 Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 Ilaria D’Acquarica, Israel Agranat
43 [GO] 2020―Apr―19 Déjà vu: Stimulating open drug discovery for SARS-CoV-2 Sean Ekins, Melina Mottin, Paulo R.P.S. Ramos, Bruna K.P. Sousa, Bruno Junior Neves, Daniel H. Foil, et al. (+6)
44 [GO] 2020―Apr―15 Boosting the arsenal against COVID-19 through computational drug repurposing Gennaro Ciliberto, Luca Cardone
45 [GO] 2020―Mar―18 Advance of promising targets and agents against 2019-nCoV in China Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou
46 [GO] 2020―Jan―30 Recent discovery and development of inhibitors targeting coronaviruses Thanigaimalai Pillaiyar, Sangeetha Meenakshisundaram, Manoj Manickam
 [1] 

46 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.006 sec